TG Therapeutics (TGTX)
NASDAQ:TGTX
Want to see TGTX full AI Analyst Report?
Top Page
TG Therapeutics
(NASDAQ:TGTX)
Select Model
Select Model
Rating:61Neutral
Price Target:
$36.00
▲(4.96% Upside)
Action:ReiteratedDate:02/28/26
The score is held back primarily by weak cash-flow conversion (persistent negative operating/free cash flow) and a major revenue/earnings-quality concern in the latest annual figures, despite improved solvency. Offsetting these risks are a favorable valuation (P/E ~10.85) and an upbeat earnings call with reaffirmed 2026 growth guidance, multiple catalysts, and ongoing buybacks, while technical signals remain broadly neutral.
Positive Factors
Commercial Momentum
Sustained, broad‑based commercial growth and record new patient starts indicate durable product‑market fit for BRIUMVI in the IV anti‑CD20 MS segment. Persistent prescriber expansion and high persistence support predictable recurring infusion revenue and medium‑term top‑line stability.
Negative Factors
Weak Cash Conversion
Chronic negative operating and free cash flow despite reported profitability shows the company still struggles to convert earnings into cash. Persistent cash burn raises reliance on external financing or asset monetization, constraining sustainable reinvestment for commercialization and manufacturing expansion.
Read all positive and negative factors
Positive Factors
Negative Factors
Commercial Momentum
Sustained, broad‑based commercial growth and record new patient starts indicate durable product‑market fit for BRIUMVI in the IV anti‑CD20 MS segment. Persistent prescriber expansion and high persistence support predictable recurring infusion revenue and medium‑term top‑line stability.
Read all positive factors
TG Therapeutics (TGTX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$5.53B
Dividend YieldN/A
Average Volume (3M)1.95M
Price to Earnings (P/E)9.6
Beta (1Y)0.60
Revenue Growth100.88%
EPS GrowthN/A
CountryUS
Employees352
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.14
Shares Outstanding159,688,260
10 Day Avg. Volume1,334,484
30 Day Avg. Volume1,954,226
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)6.64
Price to Sales (P/S)6.98
P/FCF Ratio-172.18
Enterprise Value/Market Cap1.02
Enterprise Value/Revenue9.18
Enterprise Value/Gross Profit10.98
Enterprise Value/Ebitda42.12
Forecast
1Y Price Target
$42.20Price Target Upside23.03% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)1.38
Revenue Forecast (FY)$897.41M
TG Therapeutics Business Overview & Revenue Model
Company Description
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ubl...
How the Company Makes Money
TG Therapeutics primarily makes money through product revenue from the sale of BRIUMVI in the United States. Revenue is generated by supplying BRIUMVI (a prescription biologic administered by infusion) into the healthcare channel (e.g., specialty ...
TG Therapeutics Earnings Call Summary
Earnings Call Date:Feb 26, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 11, 2026
Earnings Call Sentiment Positive
The call conveyed strong commercial momentum and rapid revenue growth for BRIUMVI, reinforced by encouraging long‑term clinical data and a clear pipeline with multiple near‑term catalysts (ENHANCE, subcutaneous pivotal, early CAR‑T activity). Financially, the company is positioned with positive cash flow expectations, share repurchase activity and reaffirmed 2026 guidance. Notable cautionary items include that reported FY2025 net income was materially boosted by a one‑time tax benefit, near‑term margin/headwind items (inventory reserve and gross‑to‑net seasonality), and elevated near‑term R&D/manufacturing investment for subcutaneous rollout. Overall, the highlights (strong growth, pipeline momentum, capital flexibility) outweigh the lowlights (one‑time accounting benefit, short‑term expense impacts and execution risks), supporting an optimistic outlook.Positive Updates
Strong Revenue Growth and Quarterly Acceleration
Total global revenue of ~$616M for FY2025, driven predominantly by U.S. BRIUMVI net sales of ~$594M. Q4 2025 U.S. net sales were $182.7M (total Q4 net product revenue $189.1M), representing ~92% year‑over‑year growth and ~20% sequential growth versus Q3.
Negative Updates
Net Income Influenced by One‑Time Tax Benefit
FY2025 reported net income of $447.2M was materially impacted by a nonrecurring income tax benefit of ~ $340M (release of deferred tax asset valuation allowance), meaning reported profitability is not fully reflective of recurring operating performance.
Read all updates
Q4-2025 Updates
Positive
Negative
Strong Revenue Growth and Quarterly Acceleration
Total global revenue of ~$616M for FY2025, driven predominantly by U.S. BRIUMVI net sales of ~$594M. Q4 2025 U.S. net sales were $182.7M (total Q4 net product revenue $189.1M), representing ~92% year‑over‑year growth and ~20% sequential growth versus Q3.
Read all positive updates
Company Guidance
TG reiterated full-year 2026 financial guidance of U.S. BRIUMVI net revenue of $825–$850 million and total global revenue of $875–$900 million, with Q1 2026 U.S. revenue expected to be roughly $185–$190 million (ex‑U.S. ~$5–$10 million); they forecast ~ $350 million of operating expenses in 2026 (excluding noncash comp) plus ~ $100 million of subcutaneous BRIUMVI manufacturing/secondary‑manufacturer start‑up costs (currently recorded to R&D), expect to continue generating positive cash flow in 2026 and beyond, and noted balance‑sheet flexibility after ending 2025 with >$600 million in current assets (≈$200M cash/cash equivalents/securities, $300M AR, $140M inventory) and completing a $100M share repurchase (~3.5M shares at $28.55 avg) with an additional $100M authorized; operationally, ENHANCE enrollment is complete with topline midyear, the subcu Phase III is ~75% enrolled with pivotal topline data late 2026/early 2027 (potential 2028 launch), and Q1 gross‑to‑net variability from deductible resets and co‑pay utilization is expected and baked into the full‑year guide.TG Therapeutics Financial Statement Overview
Summary
Income Statement
58
Neutral
Balance Sheet
72
Positive
Cash Flow
34
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 616.29M | 329.00M | 233.66M | 2.79M | 6.69M |
| Gross Profit | 515.33M | 290.52M | 219.11M | 2.52M | 5.90M |
| EBITDA | 134.36M | 49.90M | 26.10M | -213.11M | -341.97M |
| Net Income | 447.18M | 23.38M | 12.67M | -223.81M | -348.10M |
Balance Sheet | |||||
| Total Assets | 1.06B | 577.69M | 329.59M | 193.57M | 379.63M |
| Cash, Cash Equivalents and Short-Term Investments | 141.97M | 311.00M | 217.51M | 161.68M | 314.76M |
| Total Debt | 260.73M | 253.72M | 110.80M | 83.06M | 79.05M |
| Total Liabilities | 415.23M | 355.33M | 169.09M | 134.99M | 142.48M |
| Stockholders Equity | 648.02M | 222.36M | 160.50M | 58.59M | 237.15M |
Cash Flow | |||||
| Free Cash Flow | -24.99M | -40.56M | -31.41M | -176.18M | -296.04M |
| Operating Cash Flow | -24.77M | -40.52M | -31.41M | -176.17M | -295.63M |
| Investing Cash Flow | 13.80M | -1.04M | -50.65M | -20.01M | -332.00K |
| Financing Cash Flow | -89.73M | 128.53M | 72.70M | -391.00K | 41.42M |
TG Therapeutics Technical Analysis
Positive
34.30
Price Trends
30.64
Positive
30.65
Positive
31.95
Positive
Market Momentum
1.17
Negative
63.57
Neutral
63.15
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TGTX, the sentiment is Positive. The current price of 34.3 is above the 20-day moving average (MA) of 32.77, above the 50-day MA of 30.64, and above the 200-day MA of 31.95, indicating a bullish trend. The MACD of 1.17 indicates Negative momentum. The RSI at 63.57 is Neutral, neither overbought nor oversold. The STOCH value of 63.15 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TGTX.
TG Therapeutics Risk Analysis
TG Therapeutics disclosed 74 risk factors in its most recent earnings report. TG Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
TG Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | $12.27B | 12.74 | -8.82% | ― | 4.14% | -179.96% | |
61 Neutral | $5.53B | 9.62 | 101.12% | ― | 100.88% | ― | |
58 Neutral | $8.24B | -17.19 | -42.07% | ― | ― | -52.84% | |
52 Neutral | $6.00B | -35.39 | -179.05% | ― | 54.92% | 28.47% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $12.69B | -33.22 | -68.82% | ― | 20.39% | 34.00% | |
49 Neutral | $9.42B | -49.60 | -254.14% | ― | 65.83% | 28.50% |
* Healthcare Sector Average
TGTX
TG Therapeutics
34.30
-4.02
-10.49%
IONS
Ionis Pharmaceuticals
75.26
46.86
165.00%
JAZZ
Jazz Pharmaceuticals
197.83
95.05
92.48%
AXSM
Axsome Therapeutics
184.19
79.73
76.33%
RYTM
Rhythm Pharmaceuticals
88.11
26.37
42.71%
NUVL
Nuvalent
103.86
32.22
44.97%
TG Therapeutics Corporate Events
Regulatory Filings and Compliance
TG Therapeutics Files Procedural 8-K on Financial Obligation
Neutral
Mar 20, 2026
TG Therapeutics filed a very limited Form 8-K current report that merely cross-references information from Item 1.01 into Item 2.03. The filing appears to be a technical or procedural disclosure update and does not provide substantive new informat...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.